The Efficacy of IDegLira (Insulin Degludec/Liraglutide Combination) in Adults with Type 2 Diabetes Inadequately Controlled with a GLP-1 Receptor Agonist and Oral Therapy: DUAL III Randomized Clinical Trial

Sultan Linjawi, Bruce W Bode, Louis B Chaykin, Jean-Pierre Courrèges, Yehuda Handelsman, Lucine M Lehmann, Abhishek Mishra, Richard W Simpson, Sultan Linjawi, Bruce W Bode, Louis B Chaykin, Jean-Pierre Courrèges, Yehuda Handelsman, Lucine M Lehmann, Abhishek Mishra, Richard W Simpson

Abstract

Introduction: The progressive nature of type 2 diabetes necessitates treatment intensification. This often involves intensification with oral antidiabetic drugs (OADs) initially, followed by other agents, such as glucagon-like peptide-1 receptor agonists (GLP-1RAs), with the majority of patients eventually requiring insulin therapy. Therefore, this trial aimed to investigate the efficacy of IDegLira (combination of insulin degludec and liraglutide) in controlling glycemia in adults with type 2 diabetes who were inadequately controlled on a GLP-1RA and OADs.

Methods: In this 26-week open-label phase 3b trial, patients on maximum-dose GLP-1RA therapy (liraglutide once daily or exenatide twice daily) with metformin alone or with pioglitazone and/or sulfonylurea were randomized 2:1 to IDegLira once daily (n = 292) or to unchanged GLP-1RA therapy (n = 146), continuing OADs at the pre-trial dose.

Results: After 26 weeks, HbA1c reductions were superior with IDegLira versus unchanged GLP-1RA; estimated treatment difference -0.94% (-10.3 mmol/mol), p < 0.001. Mean HbA1c reduced from 7.8% to 6.4% (61.5 to 46.9 mmol/mol) with IDegLira and from 7.7 to 7.4% (60.8 to 57.1 mmol/mol) with unchanged GLP-1RA. With IDegLira, 75% and 63% of patients achieved HbA1c <7% and ≤6.5%, compared with 36% and 23% on unchanged GLP-1RA, respectively. Fasting plasma glucose and 9-point self-monitored blood glucose profiles improved significantly more with IDegLira versus unchanged GLP-1RA. The mean change in weight was +2.0 kg with IDegLira, versus -0.8 kg with unchanged GLP-1RA. Rates of confirmed hypoglycemia were low, but higher with IDegLira versus unchanged GLP-1RA. The safety profile of IDegLira was consistent with previous findings; both treatments were well tolerated and the rate of nausea was low in both groups. IDegLira improved patient-reported outcomes versus unchanged GLP-1RA.

Conclusions: IDegLira provided superior glycemic control versus unchanged GLP-1RA and represents an efficacious intensification approach in patients inadequately controlled on GLP-1RAs.

Trial registration: ClinicalTrials.gov #NCT01676116.

Funding: Novo Nordisk.

Keywords: Clinical trial; GLP-1 receptor agonist; IDegLira; Insulin therapy; Type 2 diabetes.

Figures

Fig. 1
Fig. 1
a Glycemic efficacy HbA1c over time. Mean observed values with error bars (standard error of the mean) based on FAS and LOCF imputed data. ETD is from ANCOVA analysis, and change in HbA1c (Δ) values are observed; both are based on FAS and LOCF imputed data. Dotted lines represent ADA/EASD and AACE HbA1c targets of <7.0% and ≤6.5%, respectively. b Patients achieving the HbA1c target. Treatment comparisons are from a logistic regression model based on FAS and LOCF imputed data. c FPG over time. Mean observed values with error bars (standard error of the mean) based on FAS and LOCF imputed data. ETD is from ANCOVA analysis, and change in FPG (Δ) values are observed; both are based on FAS and LOCF imputed data. d Mean nine-point SMBG profile at weeks 0 and 26. *p < 0.001 (post hoc analysis). Mean values are based on FAS, with missing profiles imputed using LOCF; SMBG was assessed with a glucose meter as plasma-equivalent values of capillary whole blood glucose. ANCOVA analysis of covariance, EOR estimated odds ratio, EOT end of trial, FAS full analysis set, FPG fasting plasma glucose, GLP-1RA glucagon-like peptide-1 receptor agonist, IDegLira insulin degludec/liraglutide combination, LOCF last observation carried forward, SMBG self-monitored blood glucose
Fig. 2
Fig. 2
Glycemic control during the first 4 weeks of the trial. Values are the median with interquartile range, based on FAS and with missing values imputed using LOCF. FAS full analysis set, GLP-1RA glucagon-like peptide-1 receptor agonist, IDegLira insulin degludec/liraglutide combination, LOCF last observation carried forward, SMBG self-monitored blood glucose
Fig. 3
Fig. 3
Body weight over time. Values are the mean with error bars (standard error of the mean), based on FAS and with missing values imputed using LOCF. Estimated treatment differences are from an ANCOVA analysis. ANCOVA analysis of covariance, FAS, full analysis set, GLP-1RA glucagon-like peptide-1 receptor agonist, IDegLira insulin degludec/liraglutide combination, LOCF last observation carried forward

References

    1. Garber AJ, Abrahamson MJ, Barzilay JI, et al. AACE comprehensive diabetes management algorithm 2013. Endocr Pract. 2013;19:327–336. doi: 10.4158/endp.19.2.a38267720403k242.
    1. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38:140–149. doi: 10.2337/dc14-2441.
    1. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32:193–203. doi: 10.2337/dc08-9025.
    1. Eckerle Mize DL, Salehi M. The place of GLP-1-based therapy in diabetes management: differences between DPP-4 inhibitors and GLP-1 receptor agonists. Curr Diabetes Rep. 2013;13:307–318. doi: 10.1007/s11892-013-0377-9.
    1. Buse JB, Bergenstal RM, Glass LC, et al. Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med. 2011;154:103–112. doi: 10.7326/0003-4819-154-2-201101180-00300.
    1. DeVries JH, Bain SC, Rodbard HW, et al. Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets. Diabetes Care. 2012;35:1446–1454. doi: 10.2337/dc11-1928.
    1. Mathieu C, Rodbard HW, Cariou B, et al. A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON) Diabetes Obes Metab. 2014;16:636–644. doi: 10.1111/dom.12262.
    1. Riddle MC, Forst T, Aronson R, et al. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1) Diabetes Care. 2013;36:2497–2503. doi: 10.2337/dc12-2462.
    1. Seino Y, Kaneko S, Fukuda S, et al. Combination therapy with liraglutide and insulin in Japanese patients with type 2 diabetes: a 36-week, randomized, double-blind, parallel-group trial. J Diabetes Investig. 2016;7:565–573. doi: 10.1111/jdi.12457.
    1. Novo Nordisk. Xultophy summary of product characteristics. 2016. . Accessed 25 Sept 2016.
    1. Gough SC, Bode B, Woo V, et al. Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes. Lancet Diabetes Endocrinol. 2014;2:885–893. doi: 10.1016/S2213-8587(14)70174-3.
    1. Gough SC, Bode BW, Woo VC, et al. One-year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26-week extension to a 26-week main trial. Diabetes Obes Metab. 2015;17:965–973. doi: 10.1111/dom.12498.
    1. Buse JB, Vilsboll T, Thurman J, et al. Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira) Diabetes Care. 2014;37:2926–2933. doi: 10.2337/dc14-0785.
    1. Rodbard HW, Bode BW, Harris SB, et al. Safety and efficacy of IDegLira added to sulphonylureas alone or sulphonylureas and metformin in insulin-naïve people with type 2 diabetes: the DUAL IV trial. Diabet Med. 2016. doi:10.1111/dme.13256(epub ahead of print).
    1. Lingvay I, Perez Manghi F, Garcia-Hernandez P, et al. Effect of insulin glargine up-titration vs insulin degludec/liraglutide on glycated hemoglobin levels in patients with uncontrolled type 2 diabetes: the DUAL V trial. JAMA. 2016;315:898–907. doi: 10.1001/jama.2016.1252.
    1. International Conference of Harmonisation. ICH harmonised tripartite guideline. Good Clin Pract 1996. . Accessed 16 Sept 2016.
    1. World Medical Association World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310:2191–2194. doi: 10.1001/jama.2013.281053.
    1. Brod M, Hammer M, Christensen T, et al. Understanding and assessing the impact of treatment in diabetes: the treatment-related impact measures for diabetes and devices (TRIM-diabetes and TRIM-diabetes device) Health Qual Life Outcomes. 2009;7:83. doi: 10.1186/1477-7525-7-83.
    1. Brod M, Christensen T, Hammer M, et al. Examining the ability to detect change using the TRIM-diabetes and TRIM-diabetes device measures. Qual Life Res. 2011;20:1513–1518. doi: 10.1007/s11136-011-9886-7.
    1. Bradley C. The diabetes treatment satisfaction questionnaire: DTSQ. Chur: Harwood Academic; 1994. p. 111–33.
    1. Garber AJ. Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability. Diabetes Care. 2011;34(Suppl 2):S279–S284. doi: 10.2337/dc11-s231.
    1. Holman RR, Thorne KI, Farmer AJ, et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med. 2007;357:1716–1730. doi: 10.1056/NEJMoa075392.
    1. Aroda VR, Bailey TS, Cariou B, et al. Effect of adding insulin degludec to treatment in patients inadequately controlled with metformin and liraglutide: a double-blind, randomized controlled trial. Diabetes Obes Metab. 2016;18:663–670. doi: 10.1111/dom.12661.
    1. Philis-Tsimikas A, Del PS, Satman I, et al. Effect of insulin degludec versus sitagliptin in patients with type 2 diabetes uncontrolled on oral antidiabetic agents. Diabetes Obes Metab. 2013;15:760–766. doi: 10.1111/dom.12115.
    1. Rodbard HW, Cariou B, Zinman B, et al. Comparison of insulin degludec with insulin glargine in insulin-naive subjects with type 2 diabetes: a 2-year randomized, treat-to-target trial. Diabet Med. 2013;30:1298–1304. doi: 10.1111/dme.12303.
    1. Swinnen SG, Dain MP, Mauricio D, et al. Continuation versus discontinuation of insulin secretagogues when initiating insulin in type 2 diabetes. Diabetes Obes Metab. 2010;12:923–925. doi: 10.1111/j.1463-1326.2010.01258.x.
    1. American Diabetes Association. Standards of medical care in diabetes—2016. Diabetes Care. 2016;39(Suppl. 1):S1–112.
    1. Simpson R, King A. Can a fixed-ratio combination of insulin degludec and liraglutide help type 2 diabetes patients to optimize glycemic control across the day? Expert Rev Clin Pharmacol. 2015;8:179–188. doi: 10.1586/17512433.2015.1017562.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren